Forum Topic News
  • Conversation: Novartis' migraine drug gets EMA approval

    • July 31, 2018 1:47 PM BST
      • Post(s)

      Novartis' migraine drug gets EMA approval

      The EMA has approved Norvartis’ Aimovig (erenumab), making it Europe’s first treatment specifically designed to prevent migraine.
      The drug works by blocking the calcitonin gene-related peptide (CGRP) receptor, thought to be involved in the transmission of the pain signals associated with migraine.
      Migraine is a complex and debilitating neurological condition that affects each individual differently. Over 610,000 people in the UK are estimated to experience chronic migraine, with the 2010 Equality Act classing migraine as a disability should the condition have a long term, substantial impact on day to day or work-related activities.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel